Immunotherapy-Chemo combo takes on stubborn thyroid and salivary tumors
NCT ID NCT03360890
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy drug docetaxel can shrink or control advanced thyroid and salivary gland cancers that are not responding to standard treatments. About 46 participants will receive both drugs intravenously every three weeks. The main goal is to see how many patients' tumors respond to the combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) and docetaxel (Taxotere)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced thyroid or salivary gland cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a small, early-phase trial (46 participants) with no control group, so results may not be definitive. The combination of immunotherapy and chemotherapy can cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVARY GLAND CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic test may spare patients from unnecessary thyroid surgery
- Can a new oral drug outsmart Radioiodine-Resistant thyroid cancer?
- Can an immune booster make radioiodine more effective against thyroid cancer?
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Can math make thyroid hormone therapy more precise?